Month over month, the 360Dx Index beat the Dow Jones Industrial Average, the Nasdaq Composite, and the Nasdaq Biotech Index.
Results support the ability of the test to not only identify hormonal therapy non-responders, but to predict their improved survival on chemotherapy.
A new trial has compared the two most prominent tests, showing that both have clear predictive ability, but leaving several other questions unanswered so far.
The study solidified how doctors should interpret and act upon an intermediate result from the breast cancer risk test in how to treat early-stage patients.
In a new analysis of the trial, researchers concluded that women over the age of 50 with recurrence scores below 25 appear to see no added benefit from adjuvant chemo.
Overall, 20 of the 25 firms in the index saw their share prices grow in May, including seven whose stocks rose more than 20 percent compared to April.
The company said it has produced documents in response to the government's civil investigative demand notice.
Test volume and revenues increased in the US, especially in prostate cancer. Meanwhile, international test volume was down but corresponding revenue increased.
Under the draft determination, the test would be covered to help assess which treatments to use in patients with advanced prostate cancer.